IPAR

Public Assessment Report for a
Medicinal Product for Human Use

Scientific Discussion

Pruridene 1 mg/g Gel
Dimetindene maleate
PA23214/002/001

The Public Assessment Report reflects the scientific conclusion reached by the Health Products Regulatory Authority (HPRA) at the end of the evaluation process and provides a summary of the grounds for approval of a marketing authorisation for a specific medicinal product for human use. It is made available by the HPRA for information to the public, after deletion of commercially sensitive information. The legal basis for its creation and availability is contained in Article 21 of Directive 2001/83/EC, as amended. It is a concise document which highlights the main parts of the documentation submitted by the applicant and the scientific evaluation carried out by the HPRA leading to the approval of the medicinal product for marketing in Ireland.

CONTENTS

I. INTRODUCTION

Based on the review of the data on quality, safety, and efficacy, the HPRA has granted a marketing authorisation for Pruridene 1 mg/g Gel from Citrine Healthcare Limited on 16th August 2024. The medicinal product is indicated in adults, the elderly and children aged 2 years or over for the short-term symptomatic relief of pruritus associated with minor inflammatory skin conditions, such as bites, stings, hives, and contact dermatitis.

This application was submitted in accordance with Article 10 (3) of Directive 2001/83/EC. This is a type of generic application that is commonly referred to as a "hybrid application". In accordance with regulatory guidance, the applicant satisfactorily demonstrated equivalence of Pruridene Gel to that of the cited reference medicinal product, Fenistil 1mg/g Gel, from GlaxoSmithKline Consumer Healthcare Lda, authorised by the Portuguese competent authority in 1975.

Pruridene Gel has been authorised as a medicinal product that is not subject to medical prescription in accordance with fulfilment of established regulatory criteria and guidance. It may be supplied through pharmacy outlets only and be advertised to the general public.

The Summary of Product Characteristics for (SmPC) for this medicinal product is available on the HPRA's website.

Name of the product	Pruridene 1 mg/g Gel
Name(s) of the active substance(s) (INN)	Dimetindene maleate
Pharmacotherapeutic classification (ATC Code)	D04AA13
Pharmaceutical form and strength(s)	Gel, 1 mg/g
Marketing Authorisation Number(s) in Ireland (PA)	PA23214/002/001
Marketing Authorisation Holder	Citrine Healthcare Limited Orchard Road Clondalkin Dublin 22 D22 V4H1 Ireland

II. QUALITY ASPECTS

II.1. Introduction

This application is for Pruridene 1mg/g Gel

II.2 Drug substance

The active substance is dimetindene maleate an established active substance described in the European Pharmacopoeia, and is manufactured in accordance with the principles of Good Manufacturing Practice (GMP)

The active substance specification is considered adequate to control the quality and meets current pharmacopoeial requirements. Batch analytical data demonstrating compliance with this specification has been provided.

II.3 Medicinal product

P.1 Composition

The drug product is a gel containing 1mg/g of active substance dimetindene maleate for cutaneous use.

The excipients in the medicinal product are listed in section 6.1 of the SmPC.
A visual description of the product is included in section 3 of the SmPC.

P.2 Pharmaceutical Development

The product is an established pharmaceutical form and its development is adequately described in accordance with the relevant European guidelines.

P.3 Manufacture of the Product

The product is manufactured in accordance with the principles of good manufacturing practice (GMP) at suitably qualified manufacturing sites.

The manufacturing process has been validated according to relevant European/ICH guidelines and the process is considered to be sufficiently validated.

P.4 Control of Other Substances (Excipients)

All ingredients comply with Ph. Eur. or are adequately controlled by the manufacturer's specifications.

P.5 Control of Finished Product

The Finished Product Specification, tests and control limits are considered appropriate for this type of product.

The analytical methods used are described in sufficient detail and are supported by validation data.

Batch analytical data for a number of batches from the proposed production site(s) have been provided and demonstrate the ability of the manufacturer to produce batches of finished product of consistent quality.

P.6 Packaging material

The approved packaging for this product is described in section 6.5 of the SmPC.

Evidence has been provided that the packaging complies with Ph. Eur./EU legislation for use with foodstuffs requirements.

P.7 Stability of the Finished Product

Stability data on the finished product in the proposed packaging have been provided in accordance with EU guidelines and support the shelf-life and storage conditions listed in sections 6.3 and 6.4 of the SmPC.

II.4 Discussion on Chemical, Pharmaceutical and Biological Aspects

The important quality characteristics of the product are well-defined and controlled. Satisfactory chemical and pharmaceutical documentation has been provided, assuring consistent quality of Pruridene 1mg/g gel.

III. NON-CLINICAL ASPECTS

III.1 Introduction

This active substance, dimetindene maleate, is a generic formulation of Fenistil 1mg/g Gel on the European market since 1975. No new preclinical data have been submitted. As such, no pre-clinical assessment has been made on the application. This is acceptable for this type of application.

III.2 Ecotoxicity/environmental risk assessment

An Environmental Risk Assessment (ERA) was submitted by the applicant. The log Kow of dimethindene is 1.65 at pH 7.4, indicating it is not a PBT substance. The PEC_{SW} value based on a refined F_{PEN} is < 0.01 µg/L, and no other environmental concerns are apparent, it is assumed that Pruridene 1 mg/g gel is unlikely to represent a risk for the environment.

III.3 Discussion on the non-clinical aspects

The pharmacodynamic, pharmacokinetic and toxicological properties of dimetindene maleate are well known. As dimetindene maleate is a widely used, well-known active substance, and this is a generic application, the applicant has not provided additional nonclinical studies and further studies are not required. The non-clinical overview on the pre-clinical pharmacology, pharmacokinetics and toxicology provided is adequate. Non-clinical findings are adequately represented in the appropriate sections of the SmPC.

IV. CLINICAL ASPECTS

IV.1 Introduction

Dimetindene maleate is a well-known active substance with established efficacy and tolerability.

The content of the SmPC approved during the national procedure is generally in accordance with that accepted for the reference product, Fenistil 1mg/g Gel, from GlaxoSmithKline Consumer Healthcare Lda, authorised in Portugal.

For this generic application, the applicant has not submitted any clinical studies. In accordance with regulatory guidance (CHMP/QWP/708282/2018, *Draft guideline on quality and equivalence of topical products*), the applicant has adequately demonstrated therapeutic equivalence of this topical gel formulation with that of the reference medicinal product through extended pharmaceutical equivalence testing.

IV.2 Pharmacokinetics
No new pharmacokinetic data were submitted, and none are required for an application of this type.

IV.3 Pharmacodynamics
No new pharmacodynamic data were submitted, and none are required for an application of this type.

IV.4 Clinical Efficacy
No new efficacy data were submitted, and none are required for an application of this type.

IV.5 Clinical Safety
No new safety data were submitted, and none are required for an application of this type.

Risk Management Plan
The MAH has submitted a risk management plan, in accordance with the requirements of Directive 2001/83/EC as amended, describing the pharmacovigilance activities and interventions designed to identify, characterise, prevent or minimise risks relating to Pruridene 1 mg/g Gel. Routine pharmacovigilance activities and routine risk minimisation measures are considered sufficient.

Summary of Safey Concerns	
Important identified risks	None
Important potential risks	None
Missing information	None

Periodic Safety Update Report (PSUR)
With regard to PSUR submission, the MAH should take the following into account:

- PSURs shall be submitted in accordance with the requirements set out in the list of Union reference dates (EURD list) provided for under Article 107c(7) of Directive 2001/83/EC and published on the European medicines web-portal. Marketing authorisation holders shall continuously check the European medicines web-portal for the
- DLP and frequency of submission of the next PSUR. · For medicinal products authorized under the legal basis of Article 10(1) or Article 10a of Directive 2001/83/EC, no routine PSURs need to be submitted, unless otherwise specified in the EURD list.
- In case the active substance will be removed in the future from the EURD list because the MAs have been withdrawn in all but one MS, the MAH shall contact that MS and propose DLP and frequency for further PSUR submissions together with a justification.

IV.6 Discussion on the clinical aspects
In accordance with the legal basis for this application and regulatory guidance, no new clinical data were submitted, and none were required.

User consultation
A suitable Patient Information Leaflet (PIL) text has been evaluated.

User testing of the PIL in accordance with Article 59(3) and Article 61(1) of Title V of Directive 2001/83/EC was replaced by bridging to the content and design of the PILs of two authorised medicinal products. This bridging approach was adequately justified by the applicant and in line with guidance.

V. OVERALL CONCLUSIONS

This application was submitted in accordance with Article 10 (3) of Directive 2001/83/EC, a type of generic application. In accordance with regulatory guidance, the applicant satisfactorily demonstrated equivalence of Pruridene Gel to that of the cited reference medicinal product, Fenistil 1mg/g Gel, from GlaxoSmithKline Consumer Healthcare Lda, authorised by the Portuguese competent authority in 1975. Fenistil 1mg/g Gel is a well-known medicinal product with a proven chemical-pharmaceutical quality and an established favourable efficacy and safety profile.

The SmPC is generally in accordance with that of the reference product. The SmPC, PIL, and labelling are satisfactory and in line with current guidelines.

User testing requirements for the PIL were fulfilled via a bridging report and in accordance with current guidance.

The MAH has provided written confirmation that systems and services are in place to ensure compliance with their pharmacovigilance obligations.

The HPRA, on the basis of the data submitted, considered that Pruridene Gel was therapeutically equivalent with the reference product and had a satisfactory risk/benefit profile, and therefore granted a marketing authorisation.

Pruridene Gel was classified as a medicinal product that is not subject to medical prescription.

VI. REVISION DATE

VII. UPDATES

UPDATE
This section reflects the significant changes following finalisation of the initial procedure.

SCOPE	PROCEDURE NUMBER	PRODUCT INFORMATION AFFECTED	DATE OF START OF PROCEDURE	DATE OF END OF PROCEDURE
New National	CRN00D148	SmPC, PIL, & IPAR	16th August 2024	15th August 2029